The global proteomics market was valued at over USD 11.8 billion in 2015. The growing incidence of target diseases such as cancer, diabetes, and cardiovascular is expected to be the major factor for market growth. Customized therapies and medicines such as protein sequencing are under research for such diseases. The sudden climatic changes, unhealthy lifestyle, and low awareness about infectious diseases in low-income countries foster the demand for better diagnosis of fatal diseases.
The goal of studying proteomics in the 21st century is to be able to detect diseases at early stages. An inordinate progress is being made in the past few years, as proteomics proves to be a very powerful tool for providing information pertaining to a broad range of diseases. Recent advancement in this field includes multiple reactions monitoring, which quantifies the proteins in the cerebrospinal fluid for the detection of later stages of multiple sclerosis.
U.S. Proteomics Market By Product, USD Million, 2013 - 2024
Furthermore, regulations and government policies support the research and development (R&D) in proteomics. The Center for Biologics Evaluation and Research regulates the approval of all the biological products related to proteomics by ensuring their safety and efficacy. The FDA is also engaged in studying the use of analytical proteomic tools for characterizing biological products and for validation of biomarkers.
The regents segment was estimated to be the largest and the fastest-growing segment in 2015, owing to factors such as widespread research in academic institutes coupled with high frequency of usage of reagent, kits, chemicals, and strips for the analysis of various biological samples.
The introduction of technologically advanced instruments, such as 2-D electrophoresis protein analyzers, is projected to exhibit significant growth over the forecast period. Instruments such as biochip analyzers and electrophoresis instruments are majorly used for the quantification of proteins.
The large-scale analysis of proteins through techniques such as x-ray crystallography, protein fractionation systems, microarray, and surface plasma resonance provides the view of molecular and cellular functions that give access to overall information of the complex processes in the living systems. The increasing importance of such studies for targeted diagnosis and treatment leads to rise in demand for the proteomics market over the forecast period.
The microarray segment was identified as the largest segment with revenue of over USD 5.6 billion in 2015. The ability of microarrays to produce more information from small samples is the major factor contributing toward its large market share. Microarray gives the advantage of label-free detection, direct and absolute quantification, and full imprint of proteins.
The introduction of new technology such as use of mass spectroscopy to analyze biological samples is expected to propel the spectroscopy industry growth over the forecast period.
Proteomics is used for various purposes such as protein expression profiling, proteome mining, structural and functional proteomics, and to study posttranslational modifications. Clinical diagnosis is also expected to foresee a lucrative growth due to its wide range of applications that include disease biomarker discovery, host-pathogen interaction, personalized medicines, the study of disease pathogenesis, and identification of drug target. Moreover, the introduction of technologically advanced instruments, increasing awareness on newer diagnostic techniques, and the increasing usage of personalized medicines are the factors responsible for its high growth.
In 2015, North America proteomics market accounted for the largest share of over 40 percent. Factors accounting for the largest share include the presence of sophisticated healthcare infrastructure, a large base of target population, and the presence of key industry players in this region. Substantial funding from the government for R&D fosters the penetration of proteomics in the region.
Asia Pacific is expected to witness lucrative growth in the forecast period with a CAGR of over 12%. Developing countries such as China and India have relatively higher chances for growth over the forecast period. Moreover, increasing private and government funding for research and rise in the proteomics-based outsourcing to the Asia Pacific region are the factors providing a potential platform for the growth of this sector.
Some key players include Roche Diagnostics, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., and GE Healthcare. These companies are involved extensively in the R&D initiatives for the development of various proteomics-related diagnostic kits and reagents. Collaboration with kit manufacturers for the development of instrument-compatible kits is a major strategic initiative undertaken by the industry players to sustain their industry position. For instance, Sygnis, a Germany-based company had acquired Expedeon Ltd. to expand its product portfolio of NGS reagents.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.